Business Description
KALA BIO is a medical research company focused on developing treatments for serious and uncommon eye conditions. Its most advanced drug candidate, KPI-012, is currently being studied in mid-stage clinical trials for patients with difficult-to-heal corneal wounds and related disorders affecting the surface of the eye. The company is also working on KPI-014, an earlier-stage treatment aimed at inherited diseases of the retina. Founded in 2009 and based in Arlington, Massachusetts, the company rebranded from Kala Pharmaceuticals to KALA BIO in 2023.
